Trospium Chloride Capsule, Extended Release
Product Images NDC 70436-174

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 70436-174). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60mg-30ct (60mg 30ct)

60mg-30ct (60mg 30ct)
Trospium Chloride Extended-Release Capsules is a type of medication that is taken once daily for usual dosages. Each capsule contains 60mg of Trospium Chloride, USP. It is recommended that this medication should be kept between 20° to 25°C (68° to 77°F). The container must be child-resistant and stored in an area where children cannot access it. This medication is manufactured by Yichang Human Well Oral Solid Dosage Plan in China and distributed by Slate Run Pharmaceuticals in Columbus, Ohio. The product code is 1000027801 Rev. 052021 and the packaging contains information related to date of expiration, lot and serialization.*
FDA Label Image

Api-structure (Api Structure)

Api-structure (Api Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
Trospium Chloride Extended-Release Capsules are a medication with a dosage of 60mg. No further information can be derived as most of the text appears to be random characters and symbols.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A comparison study was conducted between two groups: a placebo group consisting of 267 people and a treatment group consisting of an extended-release trospium chloride capsule for the same number of people. The results show a statistically significant improvement in the treatment group compared to the placebo group after 12 weeks of treatment.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
FDA Label Image

Image-a-2 (Image A 2)

Image-a-2 (Image A 2)
FDA Label Image

Image-a (Image A)

Image-a (Image A)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.